Introduction
The incidence of heart failure (HF) and chronic kidney disease (CKD) has been steadily increasing and will further increase due to ageing of the general population and better treatment of acute cardiac and renal diseases. Heart failure and CKD frequently co-exist, which can be related to common risk factors, e.g. hypertension, diabetes, and atherosclerosis, but also to common pathogenic mechanisms, such as the activation of the sympathetic nervous system, renin-angiotensin system, inflammation, and oxidative stress. Evidence also suggests that cardiac dysfunction may cause renal dysfunction, and vice versa. This current review discusses the role of the kidney in patients with HF. The definitions of CKD and acute kidney injury (AKI) are summarized in Tables 1 and 2 .
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Epidemiology and clinical significance of kidney disease in heart failure Prevalence and prognostic significance Chronic kidney disease is present in 30 -40% of the patients with HF with a greater prevalence in those with more severe symptoms. 5 -7 Multiple studies have shown worse outcomes in patients with concomitant CKD and HF. In a landmark analysis of 1906 patients, the estimated glomerular filtration rate (eGFR) was the most powerful predictor of mortality with a greater significance than the NYHA class and the left ventricular ejection fraction. 8 The strong and independent prognostic value of markers of renal function, such as serum creatinine, eGFR, and blood urea nitrogen (BUN), has been confirmed by further studies.
-13

Serum creatinine changes
An increase in serum creatinine may be present in 20-40% of patients hospitalized for HF. 9,14 -17 This increase, generally defined as worsening renal function (WRF), has been associated with male gender, 17 elderly age, 18 a history of HF, 19, 20 CKD, 16, 17 diabetes, 17, 21 anaemia, 22 hypertension, 19, 20 a larger drop in blood pressure, 18, 23, 24 and high doses of diuretics. 16, 19 Higher creatinine levels and a larger increase in serum creatinine have been associated with a longer hospital stay, increased in-hospital and long-term mortality, and higher rehospitalization rates. 9,16,17,20,25 -27 However, some studies did not find an independent association between an increase in serum creatinine and outcomes. 7, 9, 15, 16, 28, 29 Thus, differently from the absolute values, changes in serum creatinine may have a prognostic role in some, but not in all, of the patients. For example, increases in serum creatinine when angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are started are associated with long-term renal-protective effects and improved outcomes. 23, 30 Changes after diuretic therapy in patients hospitalized for HF also seem unrelated to the prognosis. 28,29,31 -33 ACR, albumin to creatinine ratio.
They are the basis for the search for new markers of kidney dysfunction (see below the specific section).
Mechanisms leading to renal dysfunction in patients with heart failure Heart failure may cause kidney dysfunction through multiple mechanisms ( Figure 1 and Table 3 ). They may interact with each other and their relative importance varies in each patient.
Importantly, as outlined in the previous section and shown in Figure 2 , short-term changes in serum creatinine levels do not necessarily evolve into long-term changes and nephron loss.
Haemodynamic abnormalities
The kidney is sensitive to haemodynamic changes, such as an increased central venous pressure ('renal afterload') and a reduced cardiac output ('renal preload'). In patients with decompensated HF, increased central venous pressure and/or intra-abdominal pressure are strong determinants of increased serum creatinine levels. 34 -39 Reduced cardiac output is another major determinant of renal impairment in HF ( Figure 3 ).
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Sympathetic hyperactivity
The kidneys are richly innervated by efferent sympathetic nerve fibres and the renal sympathetic drive is markedly increased in HF. Even mild and low-frequency stimulation of efferent sympathetic nerves enhances sodium reabsorption. Increased stimulation decreases the renal blood flow, through renal artery constriction, and stimulates renin release by the juxtaglomerular cells.
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Renin-angiotensin-aldosterone system
The renin -angiotensin-aldosterone system (RAAS) is activated in HF. Initially, angiotensin II may cause preferential vasoconstriction of the glomerular efferent arteriole, favouring glomerular filtration, despite low renal blood flow. 30, 40, 43 In the long term, RAAS activation has untoward effects on the kidney including the stimulation of inflammatory pathways, fibrosis, increased oxidative stress, and endothelial dysfunction. These mechanisms are the basis for the long-term protective effects of ACE inhibitors and ARBs. 30 
Adenosine release
Adenosine release may contribute to renal dysfunction, e.g. after high-dose furosemide. However, rolofylline, a type 1A adenosine antagonist, had no effects on long-term outcomes. 44 
Inflammation and oxidative stress
Inflammation may play a pivotal role in cardio-renal interactions. Volume overload and venous congestion cause inflammatory activation in HF. 45 
Anaemia
Anaemia is associated with poor outcomes both in HF and CKD. Renal dysfunction causes a depression of erythropoietin production. The inflammatory activation associated with HF inhibits renal erythropoietin production, causing resistance to erythropoietin and iron deficiency, through reduced absorption and decreased release from stores in macrophages and hepatocytes. 46 Effects of heart failure treatment on renal function
Many drugs used for the treatment of HF may influence renal function. Short-term changes in serum creatinine must be distinguished from long-term changes, which may be associated with nephron loss and permanent renal impairment ( Figures 3 and 4) . The effects of the major drugs treating HF patients are outlined in Table 4 .
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Markers of renal dysfunction
Traditional markers of renal function have shown major shortcomings. This has prompted the research on new biomarkers, possibly able to detect AKI at earlier stages and more related with outcomes.
Serum creatinine
Iothalamate or inulin clearances are the gold standards for measuring the GFR. However, these are time consuming and cannot be used routinely. Measurements based on serum creatinine have become routine clinical practice. Their value has been further enhanced by studies showing their prognostic value. 9, 10, 14, 26, 27 However, there are important limitations to the use of serum creatinine as a marker of renal function ( Table 5 ).
Figure 3
Changes in the GFR when the cardiac output and the renal blood flow are reduced. In the absence of a blockade of the reninangiotensin II system, preferential constriction of the efferent glomerular arteriole by angiotensin II increases the hydrostatic pressure in the glomerular capillaries allowing the maintenance of a constant GFR through an increase in the filtration fraction. This effect is blocked by renin -angiotensin inhibitors which, thus, make the kidney critically dependent only on renal blood flow. Modified from references.
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Figure 2 Mechanisms of the impairment of renal function in heart failure.
Blood urea nitrogen
Blood urea nitrogen is an important predictor of morbidity and mortality in HF. Multiple studies have shown that it has a greater prognostic value than serum creatinine. 9 -12,33,52 Paradoxically, the prognostic value of BUN may be caused by its relation to other variables, such as neurohormonal activation, protein intake, nitrogen production, and protein catabolism.
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Thus, better and earlier markers of renal dysfunction are needed. Some of them are summarized below and in Table 6 .
Cystatin-C
Cystatin-C is freely filtered by the glomerulus and then reabsorbed by the tubular epithelial cells where it is catabolized. Unlike creatinine, it is independent of the body mass, protein intake, or catabolism. Multiple studies have shown its greater accuracy as an index of the GFR. Its main advantage seems to be its greater sensitivity for the early detection of kidney dysfunction. 52,54 -56 Albuminuria Albuminuria, assessed as the albumin-to-creatinine ratio in urine, is an established criterion for the diagnosis of CKD.
1,2 Micro-and macro-albuminuria have been shown in 20 -30 and 5-10%, respectively, of the patients with HF. 57 -60 The causes are, at least partially, independent of a reduced GFR and include concomitant diabetes and/or hypertension, haemodynamic abnormalities, increased intraglomerular pressure, and endothelial damage and tubular dysfunction with reduced reabsorption. Albuminuria has been associated with an increased risk of death that remains significant after adjustment for renal function or diabetes.
-60
Tubular function markers Tubular cells may be injured at an earlier stage than the glomerulus and therefore markers of tubular damage are potentially useful for the early detection of AKI ( Figure 4 ).
Neutrophil gelatinase-associated lipocalin
Neutrophil gelatinase-associated lipocalin (NGAL) is produced by the kidney following ischaemic or toxic injury and is detectable in plasma and urine after AKI. Many studies have identified NGAL as an early marker of AKI. Elevated serum NGAL levels, measured at the time of hospital admission, can predict the development of WRF and are a prognostic marker in patients with HF. 50, 61, 62 An increase in urinary NGAL has also been shown in patients with chronic HF and has been associated with an increased mortality risk independent of the GFR.
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Kidney injury molecule 1
Kidney injury molecule-1 (KIM-1) is a marker for proximal tubular injury and is expressed in proximal tubular cells after AKI. It mediates the conversion of cells into phagocytes, which play a role in the immune response to injury. To date, it can only be measured in urine. In AKI, urinary KIM-1 has a strong predictive value for subsequent renal failure.
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N-acetyl-beta-D-glucosaminidase
N-acetyl-beta-D-glucosaminidase (NAG) is a lysosomal brush border enzyme of the proximal tubule cells, released into the urine after tubular injury. 52 Both urinary KIM-1 and NAG are consistently increased in patients with HF in the presence of tubular damage and are associated with an increased risk of HF hospitalization or death, independent of the GFR.
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Interleukin-18
Interleukin-18 (IL-18) is a cytokine quickly up-regulated in response to AKI. In a comparative analysis, IL-18 levels preceded the rise in serum creatinine, but its rise was slower compared with that of NGAL. It also has a low specificity, as, similar to other cytokines it also increases in other inflammatory conditions, such as arthritis and sepsis. To date, no studies have investigated its ability to predict AKI in patients with HF. 52 
Conclusion and future perspectives
Interactions between the heart and kidney are complex and still incompletely understood. The progressive deterioration in renal function in HF patients is a result of multiple mechanisms including increased renal venous and intra-abdominal pressure, renal hypoperfusion, neurohormonal and inflammatory activation, adenosine release, and drug therapy for HF. Impaired renal function is, therefore, more likely a marker of greater HF severity than a mechanism contributing to HF progression. The complete role of kidney dysfunction in the progression of HF is still unresolved. The prognosis seems mainly related to longterm changes in kidney function, rather than to short-term changes in serum creatinine. The importance of kidney dysfunction is also dependent on the underlying diseases (HF, but also, concomitant Role of the kidney in heart failure diabetes, hypertension, or intrinsic glomerular disease) and these need to be evaluated in each patient. New markers of glomerular and tubular function are providing additional prognostic information, and might allow an earlier detection of kidney injury. better prognostic assessment. The prevention of renal dysfunction with new therapies might also improve outcomes although strong evidence is still lacking.
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